Antibody-drug conjugate

Global Peptide Drug Conjugate Market Opportunity Clinical Trials Insight 2026

Friday, April 16, 2021 - 8:45pm

b'Global Peptide Drug Conjugate Market and Clinical Trials Insight 2026 Report Highlights:\nFirst FDA Approved Peptide Drug Conjugate: Pepaxto (Melphalan Flufenamide)\nPepaxto Clinical and Commercial Insight: Dosage, Patent, Price, Sales Forecast\nPeptide Drug Conjugate Sales Opportunity: US, Europe, Japan and South Korea\nGlobal Peptide Drug Conjugate Clinical Pipeline: > 20 Drugs\nClinical Trials Insight by Company, Country, Indication\n"Global Peptide Drug Conjugate Market and Clinical Trials Insight 2026" provides comprehensive insight on clinical and non clinical factors that are driving the peptide drug conjugate market and its impact on the global pharmaceutical market landscape.

Key Points: 
  • b'Global Peptide Drug Conjugate Market and Clinical Trials Insight 2026 Report Highlights:\nFirst FDA Approved Peptide Drug Conjugate: Pepaxto (Melphalan Flufenamide)\nPepaxto Clinical and Commercial Insight: Dosage, Patent, Price, Sales Forecast\nPeptide Drug Conjugate Sales Opportunity: US, Europe, Japan and South Korea\nGlobal Peptide Drug Conjugate Clinical Pipeline: > 20 Drugs\nClinical Trials Insight by Company, Country, Indication\n"Global Peptide Drug Conjugate Market and Clinical Trials Insight 2026" provides comprehensive insight on clinical and non clinical factors that are driving the peptide drug conjugate market and its impact on the global pharmaceutical market landscape.
  • The report has been prepared in a view to deeply profile the current market trends along with the commercial opportunity and clinical insight on only approved peptide drug conjugate Pepaxto.
  • Report also includes insight on more than 20 approved peptide drug conjugates in clinical pipeline.\nAntibody and peptide therapeutics market are two different therapeutic classes, which when combined against cancer disease development and progression are believed to deliver astonishing clinical outcomes in the patient population.
  • It few years of time period, the successful clinical establishment of the respective therapeutic class in the global market has also inclined several imperial market players of the pharmaceutical industry.

Global Peptide Drug Conjugate Market Opportunity Clinical Trials Insight 2026

Friday, April 16, 2021 - 8:45pm

b'Global Peptide Drug Conjugate Market and Clinical Trials Insight 2026 Report Highlights:\nFirst FDA Approved Peptide Drug Conjugate: Pepaxto (Melphalan Flufenamide)\nPepaxto Clinical and Commercial Insight: Dosage, Patent, Price, Sales Forecast\nPeptide Drug Conjugate Sales Opportunity: US, Europe, Japan and South Korea\nGlobal Peptide Drug Conjugate Clinical Pipeline: > 20 Drugs\nClinical Trials Insight by Company, Country, Indication\n"Global Peptide Drug Conjugate Market and Clinical Trials Insight 2026" provides comprehensive insight on clinical and non clinical factors that are driving the peptide drug conjugate market and its impact on the global pharmaceutical market landscape.

Key Points: 
  • b'Global Peptide Drug Conjugate Market and Clinical Trials Insight 2026 Report Highlights:\nFirst FDA Approved Peptide Drug Conjugate: Pepaxto (Melphalan Flufenamide)\nPepaxto Clinical and Commercial Insight: Dosage, Patent, Price, Sales Forecast\nPeptide Drug Conjugate Sales Opportunity: US, Europe, Japan and South Korea\nGlobal Peptide Drug Conjugate Clinical Pipeline: > 20 Drugs\nClinical Trials Insight by Company, Country, Indication\n"Global Peptide Drug Conjugate Market and Clinical Trials Insight 2026" provides comprehensive insight on clinical and non clinical factors that are driving the peptide drug conjugate market and its impact on the global pharmaceutical market landscape.
  • The report has been prepared in a view to deeply profile the current market trends along with the commercial opportunity and clinical insight on only approved peptide drug conjugate Pepaxto.
  • Report also includes insight on more than 20 approved peptide drug conjugates in clinical pipeline.\nAntibody and peptide therapeutics market are two different therapeutic classes, which when combined against cancer disease development and progression are believed to deliver astonishing clinical outcomes in the patient population.
  • It few years of time period, the successful clinical establishment of the respective therapeutic class in the global market has also inclined several imperial market players of the pharmaceutical industry.

MacroGenics Announces Presentations at the 2021 AACR Annual Meeting

Saturday, April 10, 2021 - 1:30pm

ROCKVILLE, MD, April 10, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc.(Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 10-15, 2021.

Key Points: 
  • ROCKVILLE, MD, April 10, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc.(Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 10-15, 2021.
  • This years AACR presentations highlight three antibody-based technologies upon which multiple molecules are being developed at MacroGenics, said Ezio Bonvini, M.D., Senior Vice President and Chief Scientific Officer of MacroGenics.
  • We are presenting pre-clinical data on MGC018, our clinical-stage, investigational antibody-drug conjugate (ADC) targeting B7-H3.
  • Together, these results illustrate the drug development potential of all three technologies MacroGenics is deploying to identify and advance promising anti-cancer drug candidates.

ImmunoGen Presents Preclinical Data on IMGC936 at the AACR Virtual Annual Meeting

Saturday, April 10, 2021 - 1:30pm

IMGC936 showed compelling anti-tumor activity against multiple patient-derived xenograft models with clinically relevant levels of ADAM9 and was well-tolerated across all models tested.

Key Points: 
  • IMGC936 showed compelling anti-tumor activity against multiple patient-derived xenograft models with clinically relevant levels of ADAM9 and was well-tolerated across all models tested.
  • We continue to enroll patients in our Phase 1 dose-escalation study of IMGC936 in multiple tumor types and look forward to sharing initial data by the end of 2021 or early 2022.
  • IMGC936 is being co-developed with MacroGenics and is currently in a Phase 1 study enrolling patients with solid tumors that express ADAM9.
  • ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.

ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer’s Disease

Thursday, April 8, 2021 - 1:02pm

In contrast, Talem has developed the TATX-112 antibodies with the goal of specifically blocking the interaction between the target and its ligand, e.g.

Key Points: 
  • In contrast, Talem has developed the TATX-112 antibodies with the goal of specifically blocking the interaction between the target and its ligand, e.g.
  • That higher specificity is expected to increase the therapeutic window by lowering the potential risk of side effects and positively impacting treatment efficacy.
  • Additionally, the targets expression profile makes this membrane protein a promising candidate for antibody-drug conjugate-based therapies.
  • Alzheimers and other neurodegenerative diseases are associated with reduced expression levels of the target and impaired receptor signaling.

Phase 1/2 Trial Initiated for Daiichi Sankyo’s Menin Inhibitor DS-1594 in Patients with Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

Wednesday, April 7, 2021 - 1:00pm

Daiichi Sankyo Company, Limited (hereafter Daiichi Sankyo) today announced the first patient has been dosed in the first-in-human phase 1/2 study of DS-1594, a selective small-molecule menin inhibitor, in adults with relapsed/refractory acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).

Key Points: 
  • Daiichi Sankyo Company, Limited (hereafter Daiichi Sankyo) today announced the first patient has been dosed in the first-in-human phase 1/2 study of DS-1594, a selective small-molecule menin inhibitor, in adults with relapsed/refractory acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
  • The trial is being conducted by The University of Texas MD Anderson Cancer Center under an existing strategic research collaboration.
  • Together with MD Anderson, we will evaluate DS-1594 as a potential therapeutic option for patients with AML or ALL who have exhausted standard treatments.
  • DS-1594 is a potent and selective small molecule menin inhibitor in clinical development in the Alpha portfolio of Daiichi Sankyo.

Vincerx Pharma To Host Key Opinion Leader Webinar on Bioconjugation and CDK9 Inhibitors for the Treatment of Hematologic and Solid Tumors

Wednesday, April 7, 2021 - 1:00pm

The event will feature presentations by KOLs Brian Druker, M.D., Knight Cancer Institute, and Anthony W. Tolcher, M.D., NEXT Oncology.

Key Points: 
  • The event will feature presentations by KOLs Brian Druker, M.D., Knight Cancer Institute, and Anthony W. Tolcher, M.D., NEXT Oncology.
  • Dr. Tolcher will discuss tackling normal tissue toxicity from antibody-drug conjugates (ADCs) and Dr. Druker will discuss CDK9 in hematologic malignancies.
  • Druker and Tolcher will be available to answer questions following the formal presentations.
  • Forward -looking statements speak only as of the date hereof, and Vincerx disclaims any obligation to update any forward-looking statements.

Exelixis Announces U.S. FDA Accepts Investigational New Drug Application for XB002 in Patients with Advanced Solid Tumors

Monday, April 5, 2021 - 1:00pm

Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of XB002 in patients with advanced solid tumors.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of XB002 in patients with advanced solid tumors.
  • Considering XB002s promising preclinical data and potential differentiation from other tissue factor-targeting antibody-drug conjugates, we look forward to initiating our phase 1 trial in patients with advanced solid tumors.
  • XB002 (formerly ICON-2) is an ADC composed of a human monoclonal antibody against tissue factor that is conjugated to a cytotoxic agent.
  • The data also demonstrated encouraging activity of XB002 in multiple solid tumor cancer models and improved tolerability compared with other tissue factor-targeting ADCs.

Fortis Therapeutics Closes $40 Million Series A Financing to Advance Novel Anti-CD46 Therapeutic to Treat Late-Stage Prostate Cancer and Multiple Myeloma

Monday, March 29, 2021 - 8:56pm

Fortis Therapeutics, Inc. , an immuno-oncology biotech developing FOR46, a novel antibody drug conjugate (ADC) against CD46, today announced the close of a $40 million Series A financing.

Key Points: 
  • Fortis Therapeutics, Inc. , an immuno-oncology biotech developing FOR46, a novel antibody drug conjugate (ADC) against CD46, today announced the close of a $40 million Series A financing.
  • The proceeds of the financing will be used to advance FOR46 in clinical trials for the treatment of relapsed or refractory multiple myeloma and metastatic castration-resistant prostate cancer (mCRPC).
  • Our preliminary clinical data is very exciting, and we are actively advancing our clinical studies in prostate cancer and multiple myeloma and pursuing additional indications.
  • Fortis Therapeutics is an immuno-oncology biotech developing a novel antibody-drug conjugate for late-stage multiple myeloma and metastatic castration-resistant prostate cancer.

European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin

Friday, March 26, 2021 - 6:00am

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., Astellas) and Seagen Inc. (Nasdaq:SGEN) today announced that a marketing authorization application (MAA) for enfortumab vedotin was accepted by the European Medicines Agency (EMA).

Key Points: 
  • Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., Astellas) and Seagen Inc. (Nasdaq:SGEN) today announced that a marketing authorization application (MAA) for enfortumab vedotin was accepted by the European Medicines Agency (EMA).
  • If approved, enfortumab vedotin would be the first antibody-drug conjugate (ADC) available in the European Union for people living with urothelial cancer.
  • We will continue to work with the CHMP toward our goal of securing marketing authorization as soon as possible.
  • In the United States, Astellas and Seagen co-promote enfortumab vedotin under the brand name PADCEV (enfortumab vedotin-ejfv).